User profiles for Bert van der Vegt
Bert van der VegtUniversity of Groningen, University Medical Center Groningen, Groningen, The Netherlands Verified email at umcg.nl Cited by 4319 |
[HTML][HTML] Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
…, MC Zwager, EGE de Vries, B van der Vegt… - Cancer treatment …, 2018 - Elsevier
Tumor-associated macrophages (TAMs) are important tumor-promoting cells in the breast
tumor microenvironment. Preclinically TAMs stimulate breast tumor progression, including …
tumor microenvironment. Preclinically TAMs stimulate breast tumor progression, including …
Intraoperative imaging in pathology-assisted surgery
The pathological assessment of surgical specimens during surgery can reduce the
incidence of positive resection margins, which otherwise can result in additional surgeries or …
incidence of positive resection margins, which otherwise can result in additional surgeries or …
[HTML][HTML] Imaging in primary Sjögren's syndrome
…, AWJM Glaudemans, B van der Vegt… - Journal of clinical …, 2020 - mdpi.com
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by
dysfunction and lymphocytic infiltration of the salivary and lacrimal glands. Besides the …
dysfunction and lymphocytic infiltration of the salivary and lacrimal glands. Besides the …
cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers
…, A van den Brink, LA Ruiz, PL Bakker, T van der Sluis… - Nature, 2022 - nature.com
Chromosomal instability (CIN) drives cancer cell evolution, metastasis and therapy resistance,
and is associated with poor prognosis 1 . CIN leads to micronuclei that release DNA into …
and is associated with poor prognosis 1 . CIN leads to micronuclei that release DNA into …
Heart failure stimulates tumor growth by circulating factors
…, AR Lyon, B van der Vegt, DJ van Veldhuisen… - Circulation, 2018 - Am Heart Assoc
Background: Heart failure (HF) survival has improved, and nowadays, many patients with
HF die of noncardiac causes, including cancer. Our aim was to investigate whether a causal …
HF die of noncardiac causes, including cancer. Our aim was to investigate whether a causal …
Tumor-specific uptake of fluorescent bevacizumab–IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study
…, WPTM Mali, E Van der Wall, PJ Van Diest… - Clinical Cancer …, 2017 - AACR
… Bert van der Vegt; Bert van der Vegt … Linssen, Esther de Boer, Bert van der Vegt,
Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. …
Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. …
[HTML][HTML] Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery
…, PJ Steinkamp, T Zhao, B van der Vegt… - Nature …, 2020 - nature.com
Cancer cell metabolism leads to a uniquely acidic microenvironment in solid tumors, but
exploiting the labile extracellular pH differences between cancer and normal tissues for clinical …
exploiting the labile extracellular pH differences between cancer and normal tissues for clinical …
[HTML][HTML] EGFR-targeted fluorescence molecular imaging for intraoperative margin assessment in oral cancer patients: a phase II trial
…, B van der Vegt, WB Nagengast, GM van Dam… - Nature …, 2023 - nature.com
Inadequate surgical margins occur frequently in oral squamous cell carcinoma surgery.
Fluorescence molecular imaging (FMI) has been explored for intraoperative margin assessment, …
Fluorescence molecular imaging (FMI) has been explored for intraoperative margin assessment, …
[HTML][HTML] Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers
…, A Jorritsma-Smit, B van der Vegt, GM van Dam - Nature …, 2018 - nature.com
During the last decade, the emerging field of molecular fluorescence imaging has led to the
development of tumor-specific fluorescent tracers and an increase in early-phase clinical …
development of tumor-specific fluorescent tracers and an increase in early-phase clinical …
[HTML][HTML] 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
…, MN Lub-de Hooge, JR de Jong, B van der Vegt… - European journal of …, 2018 - Springer
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when
HER2 status cannot be determined by standard work up | European Journal of Nuclear …
HER2 status cannot be determined by standard work up | European Journal of Nuclear …